Market Exclusive

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets downgraded to Neutral by Piper Jaffray Companies

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Today, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock was downgraded by Piper Jaffray Companies from Overweight to Neutral.

There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $50.40 per share, a potential 231.14% upside.

SEE: Market Morning: Economic Menu, Fed’s Bullard Says Remove All Tariffs, Iran Sanctions Tuesday

Some recent analyst ratings include

Recent Insider Trading Activity For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has insider ownership of 23.28% and institutional ownership of 96.72%.

 

Exit mobile version